Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Nov 17, 2020	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Open market or private sale of non-derivative or derivative security	524	$546.61	48,381
Nov 17, 2020	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Open market or private sale of non-derivative or derivative security	148	$547.12	48,233
Nov 17, 2020	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Open market or private sale of non-derivative or derivative security	216	$548.77	48,017
Nov 17, 2020	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Open market or private sale of non-derivative or derivative security	283	$549.67	47,734
Nov 17, 2020	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Open market or private sale of non-derivative or derivative security	206	$550.71	47,528
Nov 17, 2020	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Open market or private sale of non-derivative or derivative security	141	$551.48	47,387
Nov 17, 2020	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Open market or private sale of non-derivative or derivative security	73	$552.88	47,314
Nov 17, 2020	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Open market or private sale of non-derivative or derivative security	64	$553.21	47,250
Nov 17, 2020	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Open market or private sale of non-derivative or derivative security	114	$556.45	47,136
Nov 16, 2020	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	7,108	$561.39	53,764

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media